Predictors of functioning in treatment-resistant schizophrenia: the role of negative symptoms and neurocognition

被引:2
作者
Li, Yanhui [1 ]
Ang, Mei San [2 ]
Yee, Jie Yin [2 ]
See, Yuen Mei [2 ]
Lee, Jimmy [1 ,3 ,4 ]
机构
[1] Inst Mental Hlth, Singapore, Singapore
[2] Inst Mental Hlth, Res Div, Singapore, Singapore
[3] Inst Mental Hlth, Dept Psychosis, Hougang, Singapore
[4] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore
来源
FRONTIERS IN PSYCHIATRY | 2024年 / 15卷
基金
英国医学研究理事会;
关键词
treatment-resistant schizophrenia; functioning; negative symptoms; social anhedonia; neurocognition; VOCATIONAL-REHABILITATION; CLINICAL PREDICTORS; DISABILITY; COGNITION; DETERMINANTS; 1ST-EPISODE; EMPLOYMENT; DISORDER; OUTCOMES;
D O I
10.3389/fpsyt.2024.1444843
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Introduction Predictors of functioning are well-studied in schizophrenia, but much less so in treatment-resistant schizophrenia (TRS). In this study, we aim to investigate contributions of schizophrenia symptom domains and neurocognition to predict functioning in a TRS population (n = 146).Methods Participants were assessed on the Positive and Negative Syndrome Scale (PANSS), to calculate scores for five symptom factors (Positive, Negative, Cognitive, Depressive and Hostility) and two negative symptom constructs (Diminished Expressivity (DE), and Social Anhedonia (SA) as part of the Motivation and Pleasure-related dimension), based on a previously validated model, modified in accordance with EPA guidelines on negative symptoms assessment. Neurocognition was assessed with symbol coding and digit sequencing tasks from the Brief Assessment of Cognition in Schizophrenia (BACS). Functioning was assessed with the Social and Occupational Functioning Assessment Scale (SOFAS), employment status and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). Multiple regression analyses were performed on psychopathology scores and BACS scores against all three measures of functioning, controlling for age and sex. For WHODAS, regression with PANSS scores of significant symptom factors were also performed.Results A lower severity of negative symptoms in the SA dimension was the strongest predictor of higher functioning across all three functioning measures. Neurocognition, in particular processing speed and attention assessed on the symbol coding task, predicted employment. A lower severity of somatic concerns and depressive symptoms was associated with lesser self-reported disability on WHODAS.Discussion This study represents a first attempt at elucidating significant predictors of functioning in TRS. We highlight negative symptoms and neurocognition as important treatment targets to improve functioning in TRS, consistent with previous studies in general schizophrenia.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Profiling cognitive impairment in treatment-resistant schizophrenia patients
    Frydecka, Dorota
    Beszlej, Jan Aleksander
    Goscimski, Piotr
    Kiejna, Andrzej
    Misiak, Blazej
    PSYCHIATRY RESEARCH, 2016, 235 : 133 - 138
  • [42] Cariprazine: Patients with Treatment-Resistant Schizophrenia
    Aubel, Thomas
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 2327 - 2332
  • [43] A path model investigation of neurocognition, theory of mind, social competence, negative symptoms and real-world functioning in schizophrenia
    Couture, Shannon M.
    Granholm, Eric L.
    Fish, Scott C.
    SCHIZOPHRENIA RESEARCH, 2011, 125 (2-3) : 152 - 160
  • [44] Personalised transcranial magnetic stimulation for treatment-resistant depression, depression with comorbid anxiety and negative symptoms of schizophrenia: a narrative review
    Tan, Xiao Wei
    Singh, Hasvinjit Kaur Gulwant
    Koh, Jovi Zheng Jie
    Tan, Rachel Si Yun
    Tor, Phern Chern
    SINGAPORE MEDICAL JOURNAL, 2024, 65 (10) : 544 - 551
  • [45] Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia
    Meltzer, Herbert Y.
    Share, Daniel B.
    Jayathilake, Karu
    Salomon, Ronald M.
    Lee, Myung A.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2020, 40 (03) : 240 - 249
  • [46] The role of selegiline in the treatment of negative symptoms associated with schizophrenia
    Fohey, Krista D.
    Hieber, Robin
    Nelson, Leigh Anne
    ANNALS OF PHARMACOTHERAPY, 2007, 41 (05) : 851 - 856
  • [47] Difference between treatment-resistant schizophrenia and clozapine-resistant schizophrenia
    Tseng, Ping-Tao
    Chen, Mu-Hong
    Liang, Chih-Sung
    WORLD JOURNAL OF PSYCHIATRY, 2022, 12 (08): : 1102 - 1104
  • [48] Relationship Between Persistent Negative Symptoms and Findings of Neurocognition and Neuroimaging in Schizophrenia
    Ince, Ezgi
    Ucok, Alp
    CLINICAL EEG AND NEUROSCIENCE, 2018, 49 (01) : 27 - 35
  • [49] Network structure of psychotic symptoms and childhood trauma in first-episode versus treatment-resistant schizophrenia
    Liu, Zhaofan
    Wang, Xiaoying
    Deng, Hu
    Huang, Junchao
    Wang, Jue
    Chen, Wenjin
    Yang, Kebing
    Li, Wei
    Chen, Song
    Xie, Ting
    Liu, Ran
    Tian, Li
    Yang, Fude
    Tian, Baopeng
    Li, Yanli
    Li, Chiang-Shan R.
    Tan, Yunlong
    JOURNAL OF PSYCHIATRIC RESEARCH, 2025, 185 : 31 - 39
  • [50] Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia
    Semiz, Umit B.
    Cetin, Mesut
    Basoglu, Cengiz
    Ebrinc, Servet
    Uzun, Ozcan
    Herken, Hasan
    Balibey, Hakan
    Algul, Ayhan
    Ates, Alpay
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2007, 31 (06) : 1330 - 1336